Sökning: WFRF:(Ardelt P)
> (2021) >
Risk factors for re...
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients.
-
Pisano, F (författare)
-
Gontero, P (författare)
-
Sylvester, R (författare)
-
visa fler...
-
Joniau, S (författare)
-
Serretta, V (författare)
-
Larré, S (författare)
-
Di Stasi, S (författare)
-
van Rhijn, B (författare)
-
Witjes, A (författare)
-
Grotenhuis, A (författare)
-
Colombo, R (författare)
-
Briganti, A (författare)
-
Babjuk, M (författare)
-
Soukup, V (författare)
-
- Malmström, Per-Uno (författare)
- Uppsala universitet,Urologkirurgi
-
Irani, J (författare)
-
Malats, N (författare)
-
Baniel, J (författare)
-
Mano, R (författare)
-
Cai, T (författare)
-
Cha, E (författare)
-
Ardelt, P (författare)
-
Varkarakis, J (författare)
-
Bartoletti, R (författare)
-
Dalbagni, G (författare)
-
Shariat, S F (författare)
-
Xylinas, E (författare)
-
Karnes, R J (författare)
-
Palou, J (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2021
- 2021
- Engelska.
-
Ingår i: Actas urologicas espanolas. - : Elsevier BV. - 2173-5786. ; 45:6, s. 473-478
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- INTRODUCTION AND OBJECTIVES: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors that may influence the presence of residual disease at re-TUR.MATERIAL AND METHODS: In our retrospective cohort of 2451 primary T1G3 patients initially treated with BCG, pathology results for 934 patients (38.1%) who underwent re-TUR are available. 74% had multifocal tumors, 20% of tumors were more than 3 cm in diameter and 26% had concomitant CIS. In this subgroup of patients who underwent re-TUR, there was no residual disease in 267 patients (29%) and residual disease in 667 patients (71%): Ta in 378 (40%) and T1 in 289 (31%) patients. Age, gender, tumor status (primary/recurrent), previous intravesical therapy, tumor size, tumor multi-focality, presence of concomitant CIS, and muscle in the specimen were analyzed in order to evaluate risk factors of residual disease at re-TUR, both in univariate analyses and multivariate logistic regressions.RESULTS: The following were not risk factors for residual disease: age, gender, tumor status and previous intravesical chemotherapy. The following were univariate risk factors for presence of residual disease: no muscle in TUR, multiple tumors, tumors > 3 cm, and presence of concomitant CIS. Due to the correlation between tumor multi-focality and tumor size, the multivariate model retained either the number of tumors or the tumor diameter (but not both), p < 0.001. The presence of muscle in the specimen was no longer significant, while the presence of CIS only remained significant in the model with tumor size, p < 0.001.CONCLUSIONS: The most significant factors for a higher risk of residual disease at re-TUR in T1G3 patients are multifocal tumors and tumors more than 3 cm. Patients with concomitant CIS and those without muscle in the specimen also have a higher risk of residual disease.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Cáncer de vejiga no músculo-invasivo
- Enfermedad residual
- Non-muscle invasive bladder cancer
- Progresión
- Progression
- Re-resección transuretral de la vejiga
- Re-transurethral resection of the bladder
- Recurrence
- Recurrencia
- Residual disease
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Pisano, F
-
Gontero, P
-
Sylvester, R
-
Joniau, S
-
Serretta, V
-
Larré, S
-
visa fler...
-
Di Stasi, S
-
van Rhijn, B
-
Witjes, A
-
Grotenhuis, A
-
Colombo, R
-
Briganti, A
-
Babjuk, M
-
Soukup, V
-
Malmström, Per-U ...
-
Irani, J
-
Malats, N
-
Baniel, J
-
Mano, R
-
Cai, T
-
Cha, E
-
Ardelt, P
-
Varkarakis, J
-
Bartoletti, R
-
Dalbagni, G
-
Shariat, S F
-
Xylinas, E
-
Karnes, R J
-
Palou, J
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Actas urologicas ...
- Av lärosätet
-
Uppsala universitet